A recent clinical trial has found that combining the experimental drug daraxonrasib with standard chemotherapy can effectively treat advanced pancreatic cancer. The study, presented at an international cancer conference, showed that 60.7% of patients experienced tumor shrinkage, and the median time before cancer worsened was 12.8 months. While side effects were reported, they were largely manageable. Researchers are now planning a larger trial to confirm these findings.
Key facts
- The trial involved 61 patients with advanced pancreatic cancer.
- Tumors shrank in 60.7% of patients, with complete disappearance in 8.2%.
- Patients had a median progression-free survival of 12.8 months.
- Side effects included rash, diarrhea, and fatigue, mostly manageable.
- A larger Phase 3 trial, RASolute-303, is being launched.
A short AI summary in our own words. The reporting belongs to Fox News — Latest; we don't reproduce it.